Literature DB >> 27983786

Internal Structure and Preferential Protein Binding of Colloidal Aggregates.

Da Duan1, Hayarpi Torosyan1, Daniel Elnatan2, Christopher K McLaughlin3,4, Jennifer Logie3,4, Molly S Shoichet3,4, David A Agard2, Brian K Shoichet1.   

Abstract

Colloidal aggregates of small molecules are the most common artifact in early drug discovery, sequestering and inhibiting target proteins without specificity. Understanding their structure and mechanism has been crucial to developing tools to control for, and occasionally even exploit, these particles. Unfortunately, their polydispersity and transient stability have prevented exploration of certain elementary properties, such as how they pack. Dye-stabilized colloidal aggregates exhibit enhanced homogeneity and stability when compared to conventional colloidal aggregates, enabling investigation of some of these properties. By small-angle X-ray scattering and multiangle light scattering, pair distance distribution functions suggest that the dye-stabilized colloids are filled, not hollow, spheres. Stability of the coformulated colloids enabled investigation of their preference for binding DNA, peptides, or folded proteins, and their ability to purify one from the other. The coformulated colloids showed little ability to bind DNA. Correspondingly, the colloids preferentially sequestered protein from even a 1600-fold excess of peptides that are themselves the result of a digest of the same protein. This may reflect the avidity advantage that a protein has in a surface-to-surface interaction with the colloids. For the first time, colloids could be shown to have preferences of up to 90-fold for particular proteins over others. Loaded onto the colloids, bound enzyme could be spun down, resuspended, and released back into buffer, regaining most of its activity. Implications of these observations for colloid mechanisms and utility will be considered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27983786      PMCID: PMC5491102          DOI: 10.1021/acschembio.6b00791

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  48 in total

1.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

2.  Non-stoichiometric inhibition in biochemical high-throughput screening.

Authors:  Kristin Ed Coan; Johannes Ottl; Martin Klumpp
Journal:  Expert Opin Drug Discov       Date:  2011-03-15       Impact factor: 6.098

3.  Influence of additives on the properties of nanodroplets formed in highly supersaturated aqueous solutions of ritonavir.

Authors:  Grace A Ilevbare; Haoyu Liu; Junia Pereira; Kevin J Edgar; Lynne S Taylor
Journal:  Mol Pharm       Date:  2013-07-30       Impact factor: 4.939

4.  Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.

Authors:  Andrew P Combs
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

5.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

6.  Learning from PAINful lessons.

Authors:  Daniel A Erlanson
Journal:  J Med Chem       Date:  2015-02-24       Impact factor: 7.446

7.  Colloidal aggregation and the in vitro activity of traditional Chinese medicines.

Authors:  Da Duan; Allison K Doak; Lyudmila Nedyalkova; Brian K Shoichet
Journal:  ACS Chem Biol       Date:  2015-02-09       Impact factor: 5.100

8.  Detailed kinetic studies of an aggregating inhibitor; inhibition of phosphomannomutase/phosphoglucomutase by disperse blue 56.

Authors:  Hao-Yang Liu; Ziaohui Wang; Catherine Regni; Xiaoqin Zou; Peter A Tipton
Journal:  Biochemistry       Date:  2004-07-13       Impact factor: 3.162

9.  Catechol-rhodanine derivatives: Specific and promiscuous inhibitors of Escherichia coli deoxyxylulose phosphate reductoisomerase (DXR).

Authors:  Catherine Zinglé; Denis Tritsch; Catherine Grosdemange-Billiard; Michel Rohmer
Journal:  Bioorg Med Chem       Date:  2014-05-14       Impact factor: 3.641

Review 10.  Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery?

Authors:  Jonathan Bisson; James B McAlpine; J Brent Friesen; Shao-Nong Chen; James Graham; Guido F Pauli
Journal:  J Med Chem       Date:  2015-10-27       Impact factor: 7.446

View more
  8 in total

1.  Hydroxamic Acid as a Potent Metal-Binding Group for Inhibiting Tyrosinase.

Authors:  Joonhyeok Choi; Trilok Neupane; Rishiram Baral; Jun-Goo Jee
Journal:  Antioxidants (Basel)       Date:  2022-01-29

2.  Colloidal aggregation: from screening nuisance to formulation nuance.

Authors:  Ahil N Ganesh; Eric N Donders; Brian K Shoichet; Molly S Shoichet
Journal:  Nano Today       Date:  2018-03-10       Impact factor: 20.722

3.  Protein Stability Effects in Aggregate-Based Enzyme Inhibition.

Authors:  Hayarpi Torosyan; Brian K Shoichet
Journal:  J Med Chem       Date:  2019-10-17       Impact factor: 7.446

4.  A Crowding Barrier to Protein Inhibition in Colloidal Aggregates.

Authors:  Parnian Lak; Henry O'Donnell; Xuewen Du; Matthew P Jacobson; Brian K Shoichet
Journal:  J Med Chem       Date:  2021-03-24       Impact factor: 7.446

Review 5.  Preparing (Metalla)carboranes for Nanomedicine.

Authors:  Marta Gozzi; Benedikt Schwarze; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2021-03-19       Impact factor: 3.466

6.  Effect of tolytoxin on tunneling nanotube formation and function.

Authors:  Aysegul Dilsizoglu Senol; Anna Pepe; Clara Grudina; Nathalie Sassoon; Ueoka Reiko; Luc Bousset; Ronald Melki; Jörn Piel; Muriel Gugger; Chiara Zurzolo
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

Review 7.  Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands.

Authors:  Jianbo Sun; Hui Zhong; Kun Wang; Na Li; Li Chen
Journal:  Acta Pharm Sin B       Date:  2021-03-04       Impact factor: 11.413

8.  Discovery of Kinase and Carbonic Anhydrase Dual Inhibitors by Machine Learning Classification and Experiments.

Authors:  Min-Jeong Kim; Sarita Pandit; Jun-Goo Jee
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.